Novartis: Eye Diseases trials

The registry lists 11 Eye Diseases studies with Novartis as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 2Phase 2 2Phase 3 4Phase 4 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationCompletedNCT04679935Phase 4Results posted
• A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's SyndromeTerminatedNCT04035668Phase 2Results posted
• Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)CompletedNCT04005352Phase 3Results posted
• Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMDCompletedNCT03954626Phase 3Results posted
• A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.CompletedNCT02034006Phase 3Results posted
• Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected EyeCompletedNCT01986907Phase 4Results posted
• Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVOCompletedNCT01580020Phase 4Results posted
• A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye DiseaseActive, not recruitingNCT06088979Phase 2
• Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal VasculopathyCompletedNCT05666804Phase 3
• Proof of Concept Study of Binocular Videogames Versus Patching for AmblyopiaTerminatedNCT04784390Phase 1
• Intravitreal LFG316 in Patients With Advanced Age-related Macular DegenerationCompletedNCT01255462Phase 1